Literature DB >> 19025493

HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal.

Martyn A French1.   

Abstract

Individuals with human immunodeficiency virus infection who commence antiretroviral therapy when they are very immunodeficient are susceptible to immune reconstitution disorders. The most common disorders are the various forms of immune restoration disease (IRD) that appear to result from the restoration of a dysregulated immune response against pathogen-specific antigens. Essentially, any pathogen that can cause an opportunistic infection as a result of cellular immunodeficiency can provoke IRD when pathogen-specific immune responses recover during antiretroviral therapy. In resource-poor countries, Mycobacterium tuberculosis and Cryptococcus neoformans are the most significant pathogens, because the former causes substantial morbidity and the latter causes substantial mortality. IRD associated with these pathogens is characterized by severe inflammatory responses and is often referred to as immune reconstitution inflammatory syndrome. Prevention and treatment strategies for IRD are being developed, but preliminary data have demonstrated the efficacy of corticosteroid therapy in severe cases. Immune reconstitution after antiretroviral therapy may also be associated with autoimmune disease or sarcoidosis, both of which appear to have an immunopathogenesis that is different from that of IRD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19025493     DOI: 10.1086/595006

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  91 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

Review 2.  HIV infection and immune activation: the role of coinfections.

Authors:  Afroditi Boulougoura; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

Review 3.  HIV and asthma, is there an association?

Authors:  Jessica A Kynyk; Jonathan P Parsons; Michael F Para; Susan L Koletar; Philip T Diaz; John G Mastronarde
Journal:  Respir Med       Date:  2012-01-27       Impact factor: 3.415

Review 4.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

Review 5.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Authors:  Monika Müller; Simon Wandel; Robert Colebunders; Suzanna Attia; Hansjakob Furrer; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

6.  Acute renal injury in a 14-year-old with HIV/AIDS and tuberculosis.

Authors:  Kristopher R Bosse; Eric A Russell; Kudakwashe R Chikwava; Richard M Rutstein; Elizabeth Lowenthal
Journal:  Pediatr Infect Dis J       Date:  2013-09       Impact factor: 2.129

Review 7.  Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy.

Authors:  Sarah M Kranick; Avindra Nath
Journal:  Continuum (Minneap Minn)       Date:  2012-12

Review 8.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

9.  [Severe aseptic leucoencephalopathy. Manifested as immune reconstitution inflammatory syndrome in Caucasian and African patients].

Authors:  A Ringelstein; C Oelschlaeger; G Arendt; C Mathys; R Dziewas; T Niederstadt; D Reichelt; M Hasselblatt; I W Husstedt; A Saleh
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

Review 10.  The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum.

Authors:  David B Meya; Yukari C Manabe; David R Boulware; Edward N Janoff
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.